… This systematic review aims to assess the literature … systemic therapies, or therapeutic
combinations, in association with the most common primary treatments for high-risk prostate cancer…

… In the present systematic review and NMA of systemic therapies for patients with mHSPC,
we indirectly compared data from phase III clinical trials. ARIs were identified as effective …

… of care for men with metastatic castration-resistant prostate cancer (mCRPC), but recently …
therapy. This review was undertaken to determine which systemic therapies improve cancer- …

… efforts to explore the role of additional systemic therapy earlier in the disease course. …
in the expansion of systemic therapies in metastatic castration-naïve prostate cancer (mCNPC). …

… The management of metastatic prostate cancer (mPCa) has changed over the past ten …
prostate cancer (PCa) including chemotherapy (docetaxel, cabazitaxel), new hormonal therapies (…

… Systemic therapy has become an increasingly important component of treatment of advanced
prostate cancer… the key steps in the recent evolution of systemic therapy of prostate cancer. …

… of systemic chemotherapy for metastatic prostate cancer have been disappointing. Single
agents evaluated in men with hormone-refractory prostate cancer … or combination therapy have …

… one-quarter of new cancer diagnoses in American men with … for metastatic PC is
androgen-deprivation therapy (ADT) with/… -resistant prostate cancer (mCRPC), characterized by …

… For the last 60 years, hormonal therapy has been the cornerstone of treatment of … prostate
cancer. Unfortunately, hormonal therapy is purely palliative and improved systemic therapies …

… provide the current recommendations for systemic therapy in metastatic CRPC. … prostate
cancer, management of prostate cancer recurrence based solely on detection of serum prostate-…